Sei Investments Co. Has $161.41 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Sei Investments Co. boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,158,099 shares of the biopharmaceutical company’s stock after purchasing an additional 65,384 shares during the quarter. Sei Investments Co.’s holdings in Gilead Sciences were worth $161,406,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of GILD. Vermillion & White Wealth Management Group LLC boosted its holdings in shares of Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 85 shares during the period. Strategic Investment Solutions Inc. IL acquired a new stake in Gilead Sciences during the fourth quarter worth approximately $25,000. Quattro Advisors LLC acquired a new stake in Gilead Sciences during the fourth quarter worth approximately $26,000. Wealth Preservation Advisors LLC boosted its holdings in shares of Gilead Sciences by 60.0% during the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 81 shares during the period. Finally, Ares Financial Consulting LLC acquired a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $28,000. 83.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

GILD has been the subject of several research reports. Royal Bank Of Canada dropped their price target on Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating for the company in a report on Tuesday, July 7th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $155.00 price target on shares of Gilead Sciences in a research report on Monday, July 6th. Weiss Ratings downgraded shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, May 28th. The Goldman Sachs Group raised their target price on shares of Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a report on Friday, April 17th. Finally, Leerink Partners cut shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $146.00 to $127.00 in a research report on Tuesday. Twenty-five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $158.33.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $126.29, for a total transaction of $1,894,350.00. Following the sale, the chief executive officer owned 607,133 shares of the company’s stock, valued at approximately $76,674,826.57. The trade was a 2.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $125.40, for a total transaction of $376,200.00. Following the transaction, the chief financial officer owned 171,646 shares of the company’s stock, valued at $21,524,408.40. This trade represents a 1.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 77,000 shares of company stock worth $9,978,740 over the last quarter. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $130.86 on Friday. Gilead Sciences, Inc. has a 12-month low of $108.46 and a 12-month high of $157.29. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The business’s 50-day moving average price is $129.55 and its two-hundred day moving average price is $135.54. The stock has a market cap of $162.47 billion, a PE ratio of 17.83 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. During the same quarter in the prior year, the business earned $1.81 earnings per share. The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, analysts expect that Gilead Sciences, Inc. will post -0.77 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Investors of record on Monday, June 15th were paid a $0.82 dividend. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.28 annualized dividend and a yield of 2.5%. Gilead Sciences’s dividend payout ratio is presently 44.69%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.